Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 7/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.40 |
| ▸ | CA4 | P22748 | 6/20 | 0.40 |
| ▸ | CA9 | Q16790 | 6/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SOD1 | P00441 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28399593 | 0.86 | GSTP1 (0.39) | GSTP1MAOBMAOAACHECA12 | |
| SCHEMBL3204571 | 0.83 | GSTP1 (0.52) | GSTP1MAOBMAOAACHECA12 | |
| SCHEMBL16395285 | 0.79 | GSTP1 (0.40) | GSTP1MAOBMAOAACHECA12 | |
| SCHEMBL4808501 | 0.79 | MAOB (0.51) | GSTP1MAOBMAOACA12CA4 | |
| SCHEMBL28406655 | 0.79 | MEN1 (0.47) | MAOBMAOAALDH1A1GAA | |
| SCHEMBL15940050 | 0.78 | GSTP1 (0.42) | GSTP1MAOBMAOAACHECA12 | |
| SCHEMBL2781336 | 0.77 | SOD1 (0.39) | POLBHSD17B10SOD1KDM4EALDH1A1 | |
| SCHEMBL5540730 | 0.77 | SOD1 (0.47) | SOD1 | |
| SCHEMBL3830326 | 0.77 | CA12 (0.53) | GSTP1MAOBMAOAACHECA12 | |
| SCHEMBL15747176 | 0.77 | MAOB (0.44) | GSTP1MAOBMAOAACHECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107344940-B | BTK inhibitors and uses thereof | 广东东阳光药业有限公司 | 2020-04-21 | — | — | CN | disclosed |
| EP-3145512-B1 | SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS | JIANGSU HENGRUI MEDICINE CO (CN) | 2019-07-17 | — | — | EP | disclosed |
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10174026-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-12-04 | — | — | US | disclosed |
| EP-2968282-B1 | HISTONE DEMENTHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873697-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170313702-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-9738637-B2 | Histone demethylase inhibitors | Celgene Quantical Research, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-7405310-B2 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2008-07-29 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | MEDIVIR AB (SE) | 2008-03-20 | — | — | US | disclosed |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2006-07-27 | — | — | US | disclosed |
| US-20050240035-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-10-27 | — | — | US | disclosed |
| US-6894177-B2 | Intermediate compounds of non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2005-05-17 | — | — | US | disclosed |
| US-6716850-B2 | ESPECIALLY N-(NITROGEN HETEROAR-2-YL)-SUBSTITUTED TETRAHYDROCYCLOPROPA(C)CHROMEN-1-UREAS AND THIOUREAS; TREATING HIV-1, PARTICULARLY A DRUG ESCAPE MUTANT. | MEDIVIR AB (SE) | 2004-04-06 | — | — | US | disclosed |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | MEDIVIR AB (SE) | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240035-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, TYMP, PNP | GSTP1 788/4885MAOB 1060/4885MAOA 1172/4885 |
| US-20030069224-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | GSTP1 2869/4885MAOB 2938/4885MAOA 3680/4885 |
| US-20170313702-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | GSTP1 1721/4885MAOB 588/4885MAOA 537/4885 |
| US-20190092771-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | GSTP1 1721/4885MAOB 588/4885MAOA 537/4885 |
| US-20030187266-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, NAT10, NSUN2 | GSTP1 2869/4885MAOB 2938/4885MAOA 3680/4885 |
| US-20180105521-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5A | GSTP1 1721/4885MAOB 588/4885MAOA 537/4885 |
| US-10144737-B2 | Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors | BTK, BCL9, LCK | GSTP1 1728/4885MAOB 1675/4885MAOA 3393/4885 |
| US-20060167055-A1 | Non-nucleoside reverse transcriptase inhibitors | POLR2H, POLR2E, POLR1E | GSTP1 2559/4885MAOB 1874/4885MAOA 2680/4885 |
| US-10174026-B2 | Histone demethylase inhibitors | KDM1B, KDM1A, KDM5A | GSTP1 1721/4885MAOB 588/4885MAOA 537/4885 |
| US-20080070951-A1 | Non-Nucleotide Reverse Transcriptase Inhibitors | RCOR1, RRM2, POLR1A | GSTP1 2348/4885MAOB 2201/4885MAOA 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.